Meet cardiologist Professor Renato Lopes and learn more about the ground breaking AUGUSTUS trial in patients with atrial fibrillation with ACS and/or PCI in these video interviews.
What unmet needs still need to be addressed in AF, particularly surrounding anticoagulation therapy and stroke prevention?
Professor Lopes describes the gaps that still exist as new therapies have not been thoroughly tested in all patients and clinical conditions. Learn about the areas where we still have gaps to close.
What made the AUGUSTUS trial such a game-changer and why was it needed?
Professor Lopes describes the 2x2 factorial design which involved 4,600 patients with atrial fibrillation and ACS with or without PCI and independently assessed the contribution on bleeding and on ischaemic events reduction in bleeding with apixaban and warfarin.
Does this mean that antithrombotic strategies are better without aspirin? Is less really more?
Professor Lopes describes how the recent meta-analysis has shown that classic triple therapy with aspirin, a P2Y inhibitor and warfarin should be avoided as these drug combinations have the worst bleeding outcomes.
What was the ENTRUST study and how does this provide context to the AUGUSTUS trial?
Professor Lopes summarises the ENTRUST-AF study comparing edoxaban in a double therapy with a P2Y12 inhibitor vs. warfarin as part of a triple therapy which has been important in adding to the body of knowledge in this field.
Developed by EPG Health for Medthority. This content has been developed independently of the sponsors who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.